Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Fig. 6

Proliferative capacity of T cells post gemcitabine. Ten pancreatic cancer patients were sampled during the first cycle of gemcitabine treatment, where gemcitabine was given once weekly for 3 weeks, followed by a resting period. Blood samples were collected at day 1, 8, 15 and 29 always before gemcitabine was given that day. The capacity of T cells to proliferate in response to CD3 antibody and IL-2 stimulation was assessed by Alarmar Blue assay. Measurements were taken at 0, 24, 48, and 72 h at 570 and 595 nm. Grey lines Healthy controls (HC), Black lines patients. Statistical differences between HCs and patients were assessed by unpaired t-test with Welch’s correction (*P < 0.05, **P < 0.01)

Back to article page